On Sunday, President Donald Trump announced his intention to sign an executive order aimed at reducing prescription drug prices in the United States. The policy, which he previously attempted to implement during his first term, seeks to base the payments for certain medicines on the prices paid for those drugs in other developed countries. This approach, sometimes referred to as the 'most favored nation' pricing model, would mean that the U.S. government would not pay more for specific medications than the lowest price paid by other comparable countries. The original version of this policy faced significant opposition from the pharmaceutical industry and was subject to legal challenges, with critics arguing it could limit access to some drugs or stifle innovation. Supporters, however, argue that Americans pay some of the highest drug prices in the world and that aligning U.S. prices with those abroad could provide significant savings for patients and the government. The announcement comes as drug pricing remains a major issue for American voters and policymakers, with ongoing debates about how to make medications more affordable while ensuring continued investment in pharmaceutical research and development. Details about the timing and scope of the new executive order have not yet been released.